Dose Escalation Study Evaluating Stereotactic Radiosurgery for Liver Malignancies
This study is intended to establish the practicality of treating cancer in the liver with precisely administered single fractions of high-energy radiation using a radiosurgical (cross-firing) technique. A second purpose is to establish a safe dose for such therapy. Finally, the efficacy of radiosurgical ablation of liver tumors, in terms of radiographic response, will be measured.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Joanne Imperial
- Iris C. Gibbs, MD, FACR
- George A. Fisher Jr.
- Mindie H. Nguyen, MD, MAS, FAASLD, AGAF
- Albert Koong, MD, PhD
- George Yang
- procedure : Stereotactic radiosurgery
Phase: Phase 1
Ages Eligible For Study:
All the following criteria must be met: - Liver tumors not to exceed 5 cm in diameter. If this size can be increased at all, that would be beneficial as many liver lesions present at a larger size given the lack of symptoms until they are larger and adequate hepatic function with albumin >3.0, total bilirubin <3, INR 1.8. In the case of patients with known or 7 Dose Escalation Study Evaluating Stereotactic Radiosurgery for Liver Malignancies suspected cirrhosis, patients must have creatinine <1.5 and cannot have uncontrolled ascites, encephalopathy, active or recent gastrointestinal bleed (GIB). - Age > 18 years old - Histologically confirmed hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHCC), or metastatic adenocarcinoma of the breast/colon. Metastatic tumors of other histologic types or sites of origin may be included if the patients have a life expectancy of 6 months or greater. In the case of suspected HCC in patients with known cirrhosis, noninvasive criteria recommended by the European Association for the Study of Liver Diseases may be used. Hypervascular lesions > 2cm with alpha-fetoprotein (AFP) > 400ng/mL or hypervascular lesions >2cm on at least 2 imaging studies. - Unresectable disease as determined by a surgeon - Eastern Clinical Oncology Group performance status 0,1 or 2 - No chemotherapy within 1 month of registration - No prior radiotherapy to the liver or upper abdominal area - Life expectancy > 6 months - Patients with IHCC or HCC with distant metastasis are not eligible for this study. - For colon cancer patients with metastatic tumor of the liver who are not amenable to surgical resection due to the efficacy of removal of simultaneous lung and liver metastasis.